£5.1M
The financing will support clinical trials, product development and team expansion as the business pursues international regulatory approvals.
"Our work in the US and the success of the trials we have run to date have demonstrated the potential of our technology and encouraged us to pursue other applications. With this financing and the backing of our investors we can accelerate our mission of delivering effective and non-invasive solutions for some of the most common and debilitating medical conditions."
N
Neurovalens—Belfast, UKIQ Capital + 5 others
